• Alexander W Gotta.
• State University of New York, Great Neck, Brooklyn 11021-2912, USA. alexandcolleen@prodigy.net
• Curr Opin Invest Dr. 2002 Feb 1;3(2):240-5.

AbstractPharmacia (formerly Searle), in collaboration with Pfizer and Yamanouchi, has developed valdecoxib, a second-generation cyclooxygenase (COX)-2 inhibitor as a follow-up to celecoxib, for the treatment of arthritis. Pharmacia filed an NDA with the FDA in March 2001 for the treatment of acute pain, dysmenorrhea, osteoarthritis (OA) and rheumatoid arthritis (RA). At this time, Pharmacia anticipated a 12-month review [402883]. In June 2001, launch was anticipated in 2002 [412616], and in November 2001, valdecoxib was granted FDA approval [429715]. The company claims that valdecoxib has improved potency and broader therapeutic range than other COX-2 inhibitors including celecoxib, and has the potential for once-daily dosing [287279], [313957]. By 1999, due to the poor water solubility of valdecoxib, Searle was also developing the prodrug parecoxib [324667]. Valdecoxib has been described by Searle as almost superimposable at the site critical for COX-2 inhibition, a structural side pocket in the enzyme which coincides with the sulfonamide group of the drug [324667]. In April 2000, Morgan Stanley Dean Witter estimated sales would be US $400 million in 2003, rising to US $750 million in 2004 [375906]. In April 2001, Merrill Lynch predicted world sales of US $460 million in 2002, rising to $1,065 million in 2005 [420574]. In September 2000, Merrill Lynch reported that additional pain data were being accumulated for this drug, the possible inclusion of which could push filing back to later in the first half of 2001 [382577]. In May 2001, Merrill Lynch expected launch in 2002 [411811]. In August 2001, Lehman Brothers predicted that launch would take place in thefirst half of 2002 and the product would make peak sales of US $1,500 million [420809]. Credit Suisse predicted in this month that total sales would reach US $330 million in 2002, rising to US $1832 million in 2004 [422318]. In September 2001, Morgan Stanley expected launch in the first half of 2002 [427113]. By October 2001, Credit Suisse had revised its sales predictions to US $180 million in 2002, US $790 million in 2003 and US $1,430 in 2004 [427185].

32 keywords...

hide…